JPH09512267A - 因子ix用処方 - Google Patents
因子ix用処方Info
- Publication number
- JPH09512267A JPH09512267A JP7527660A JP52766095A JPH09512267A JP H09512267 A JPH09512267 A JP H09512267A JP 7527660 A JP7527660 A JP 7527660A JP 52766095 A JP52766095 A JP 52766095A JP H09512267 A JPH09512267 A JP H09512267A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- factor
- glycine
- concentration
- sucrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.因子IX、グリシン、および冷凍保護剤からなる組成物。 2.該冷凍保護剤がスクロースおよびマンニトールからなる群より選択される メンバーである請求項1の組成物。 3.該冷凍保護剤がスクロースである請求項1の組成物。 4.該スクロース濃度が約0.5ないし2%である請求項3の組成物。 5.該スクロース濃度が約1%である請求項4の組成物。 6.該グリシン濃度が約0.1ないし0.3Mである請求項1の組成物。 7.該グリシン濃度が約0.2ないし0.3Mである請求項6の組成物。 8.該グリシン濃度が約0.26Mである請求項7の組成物。 9.さらに塩化カルシウムからなる請求項1の組成物。 10.さらに界面活性剤からなる請求項1の組成物。 11.該界面活性剤がポリソルベートである請求項10の組成物。 12.該ポリソルベート濃度が約0.005ないし0.05%である請求項11 の組成物。 13.該ポリソルベート濃度が約0.005%である請求項11の組成物。 14.さらに緩衝化剤からなる請求項1の組成物。 15.さらに緩衝化剤からなる請求項10の組成物。 16.該緩衝化剤がヒスチジン、リン酸塩、トリス、およびジエタノールアミ ンからなる群より選択されるメンバーである請求項15の組成物。 17.該緩衝化剤がヒスチジンである請求項16の組成物。 18.該ヒスチジン濃度が約10mMである請求項17の組成物。 19.因子IX、グリシン、および緩衝化剤、冷凍保護剤ならびに界面活性剤か らなる群より選択されるメンバーからなる組成物。 20.因子IX、グリシン、ヒスチジン、およびポリソルベートからなる請求項 19の組成物。 21.因子IX、グリシン、ヒスチジン、およびスクロースからなる請求項19 の組成物。 22.さらにポリソルベートからなる請求項21の組成物。 23.因子IX、グリシン、リン酸ナトリウム、スクロース、およびポリソルベ ートからなる請求項19の組成物。 24.因子IX、グリシン、リン酸ナトリウム、およびスクロースからなる請求 項19の組成物。 25.因子IX、グリシン、リン酸カリウム、スクロース、およびポリソルベー トからなる請求項19の組成物。 26.因子IX、グリシン、リン酸カリウム、およびスクロースからなる請求項 19の組成物。 27.因子IX、グリシン、トリス、スクロース、およびポリソルベートからな る請求項19の組成物。 28.因子IX、グリシン、トリス、およびスクロースからなる請求項19の組 成物。 29.因子IX、グリシン、塩化カルシウム、ポリソルベート、およびスクロー スからなる請求項19の組成物。 30.因子IX、グリシン、トリス、塩化カルシウム、ポリソルベート、および スクロースからなる請求項19の組成物。 31.因子IX、グリシン、ジエタノールアミン、ポリソルベート、およびスク ロースからなる請求項19の組成物。 32.該因子IX濃度が約0.4ないし20mg/mlである請求項19の組成 物。 33.該因子IX濃度が約0.1ないし10mg/mlである請求項32の組成 物。 34.該因子IX濃度が約0.5ないし10mg/mlである請求項19の組成 物。 35.該グリシン濃度が約0.1ないし0.3Mである請求項19の組成物。 36.該グリシン濃度が約0.26Mである請求項35の組成物。 37.該緩衝化剤が約5ないし30mMのヒスチジンである請求項19の組成 物。 38.該ヒスチジン濃度が約10mMである請求項37の組成物。 39.該冷凍保護剤が約0.5ないし2%のスクロースである請求項19の組 成物。 40.該スクロース濃度が約1%である請求項39の組成物。 41.該界面活性剤が約0.005ないし0.05%のポリソルベートである請 求項20の組成物。 42.該ポリソルベート濃度が約0.005%である請求項41の組成物。 43.0.75mg/mlの因子IX、0.26Mグリシン、10mMヒスチジン 、1%スクロース、および0.005%ポリソルベートからなる組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/233,663 | 1994-04-26 | ||
US08/233,663 US6372716B1 (en) | 1994-04-26 | 1994-04-26 | Formulations for factor IX |
PCT/US1995/004263 WO1995028954A1 (en) | 1994-04-26 | 1995-04-06 | Formulations for factor ix |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006141780A Division JP4789698B2 (ja) | 1994-04-26 | 2006-05-22 | 因子ix用処方 |
JP2007156252A Division JP2007224052A (ja) | 1994-04-26 | 2007-06-13 | 因子ix用処方 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09512267A true JPH09512267A (ja) | 1997-12-09 |
Family
ID=22878181
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7527660A Withdrawn JPH09512267A (ja) | 1994-04-26 | 1995-04-06 | 因子ix用処方 |
JP2006141780A Expired - Lifetime JP4789698B2 (ja) | 1994-04-26 | 2006-05-22 | 因子ix用処方 |
JP2007156252A Withdrawn JP2007224052A (ja) | 1994-04-26 | 2007-06-13 | 因子ix用処方 |
JP2009267797A Withdrawn JP2010077148A (ja) | 1994-04-26 | 2009-11-25 | 因子ix用処方 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006141780A Expired - Lifetime JP4789698B2 (ja) | 1994-04-26 | 2006-05-22 | 因子ix用処方 |
JP2007156252A Withdrawn JP2007224052A (ja) | 1994-04-26 | 2007-06-13 | 因子ix用処方 |
JP2009267797A Withdrawn JP2010077148A (ja) | 1994-04-26 | 2009-11-25 | 因子ix用処方 |
Country Status (11)
Country | Link |
---|---|
US (1) | US6372716B1 (ja) |
EP (1) | EP0758248B1 (ja) |
JP (4) | JPH09512267A (ja) |
AT (1) | ATE244015T1 (ja) |
AU (1) | AU695084B2 (ja) |
CA (1) | CA2182200C (ja) |
DE (1) | DE69531204T2 (ja) |
DK (1) | DK0758248T3 (ja) |
ES (1) | ES2202356T3 (ja) |
PT (1) | PT758248E (ja) |
WO (1) | WO1995028954A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010530846A (ja) * | 2007-06-01 | 2010-09-16 | アコロジックス インコーポレイティッド | 高温で安定なペプチド製剤 |
US10370456B2 (en) | 2004-09-09 | 2019-08-06 | Genentech, Inc. | Process for concentration of antibodies and therapeutic products thereof |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5770700A (en) * | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
US7786070B2 (en) | 1997-09-10 | 2010-08-31 | Novo Nordisk Healthcare A/G | Subcutaneous administration of coagulation factor VII |
WO2001082943A2 (en) | 2000-05-03 | 2001-11-08 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor vii |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US20080050367A1 (en) * | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) * | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
AU2002225681A1 (en) * | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
HUP0402315A3 (en) | 2001-12-21 | 2009-03-30 | Novo Nordisk Healthcare Ag | Liquid composition of factor vii polypeptides |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
CN1671410B (zh) | 2002-06-21 | 2010-05-12 | 诺和诺德医疗保健公司 | 因子ⅶ多肽的稳定化固体组合物 |
JP2006516639A (ja) * | 2003-02-01 | 2006-07-06 | ニユーララブ・リミテツド | 可溶性A−βに対する抗体を生成させるための能動免疫 |
US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
AU2004241698A1 (en) | 2003-05-23 | 2004-12-02 | Novo Nordisk Health Care Ag | Protein stabilization in solution |
PE20050627A1 (es) * | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
ES2382157T3 (es) | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Composición líquida de polipépttidos del factor VII |
CA2534028A1 (en) | 2003-08-14 | 2005-02-24 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
EP3378470A1 (en) | 2003-12-19 | 2018-09-26 | Novo Nordisk Health Care AG | Stabilised compositions of factor vii polypeptides |
ES2390082T5 (es) * | 2004-06-30 | 2018-01-19 | Nektar Therapeutics | Conjugados de resto de Factor IX y polímeros |
PE20061329A1 (es) * | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
JP2008524247A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのアミロイドβ抗体 |
WO2006066049A2 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
JP2008528638A (ja) * | 2005-01-28 | 2008-07-31 | ワイス | ポリペプチドの安定化液体処方 |
ES2569917T3 (es) | 2005-06-21 | 2016-05-13 | Xoma (Us) Llc | Anticuerpos y fragmentos de los mismos que se unen a IL-1beta |
PL1942868T5 (pl) | 2005-11-01 | 2023-12-27 | Wyeth Llc | Roztwór chlorku sodu do odtwarzania lub rozcieńczania leku |
WO2007062040A1 (en) * | 2005-11-22 | 2007-05-31 | Wyeth | Immunoglobulin fusion protein formulations |
US8784810B2 (en) * | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US7695718B2 (en) | 2006-12-20 | 2010-04-13 | Xoma Technology Ltd. | Methods for the treatment of IL-1β related diseases |
US8003097B2 (en) * | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
CA2684323A1 (en) * | 2007-04-18 | 2008-10-30 | Janssen Alzheimer Immunotherapy | Prevention and treatment of cerebral amyloid angiopathy |
PL2182983T3 (pl) | 2007-07-27 | 2014-10-31 | Janssen Alzheimer Immunotherap | Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta |
JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
CA2710252C (en) | 2007-12-20 | 2017-03-28 | Xoma Technology Ltd. | Methods for the treatment of gout |
WO2009082648A1 (en) * | 2007-12-21 | 2009-07-02 | Inspiration Biopharmaceuticals, Inc. | Stabilized factor ix formulations containing trehalose |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
PL2465542T3 (pl) * | 2008-12-16 | 2015-06-30 | Genzyme Corp | Koniugaty białko-oligosacharyd |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
DK2663580T3 (en) | 2011-01-10 | 2017-03-13 | Ct Atlantic Ltd | COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTI-BINDING ANTIBODIES |
US20140093514A1 (en) | 2011-06-03 | 2014-04-03 | University Of Zurich | Magea3 binding antibodies |
JP2014524891A (ja) | 2011-06-03 | 2014-09-25 | シーティー アトランティック リミテッド | Magea3結合抗体 |
WO2013096516A1 (en) | 2011-12-19 | 2013-06-27 | Xoma Technology Ltd. | Methods for treating acne |
CA2863224A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
JP2015509091A (ja) | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | ヒト化抗体 |
US20150252345A1 (en) * | 2012-09-25 | 2015-09-10 | Biogen Idec Ma Inc. | Methods of Using FIX Polypeptides |
WO2014075033A2 (en) * | 2012-11-09 | 2014-05-15 | Puget Sound Blood Center | Protein stabilizing factors |
WO2014138725A1 (en) | 2013-03-08 | 2014-09-12 | Curators Of The University Of Missouri | Methods and compositions for the treatment and/or prevention of type 1 diabetes |
TWI788044B (zh) | 2013-03-15 | 2022-12-21 | 美商百歐維拉提夫治療公司 | 因子ix多肽調配物 |
CN105593242B (zh) | 2013-07-11 | 2020-11-06 | 斯克利普斯研究所 | 卷曲螺旋免疫球蛋白融合蛋白及其组合物 |
WO2015017146A2 (en) | 2013-07-18 | 2015-02-05 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
EP3022221B1 (en) | 2013-07-18 | 2021-09-15 | Taurus Biosciences, LLC | Humanized antibodies with ultralong complementarity determining regions |
US10286078B2 (en) | 2013-09-13 | 2019-05-14 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
US9913818B2 (en) | 2013-10-09 | 2018-03-13 | Nestec S.A. | Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome |
EP3057994B1 (en) | 2013-10-15 | 2020-09-23 | The Scripps Research Institute | Peptidic chimeric antigen receptor t cell switches and uses thereof |
ES2741308T3 (es) | 2013-10-15 | 2020-02-10 | Scripps Research Inst | Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos |
CN106456589B (zh) | 2013-12-18 | 2020-07-07 | 斯克利普斯研究所 | 修饰的治疗剂、订合的肽脂质缀合物及其组合物 |
AU2015236340B2 (en) | 2014-03-24 | 2020-02-06 | Bioverativ Therapeutics Inc. | Lyophilized factor IX formulations |
US10800828B2 (en) | 2015-03-26 | 2020-10-13 | The Scripps Research Institute | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer |
US11091546B2 (en) | 2015-04-15 | 2021-08-17 | The Scripps Research Institute | Optimized PNE-based chimeric receptor T cell switches and uses thereof |
NZ737400A (en) | 2015-06-01 | 2019-09-27 | Medigene Immunotherapies Gmbh | T cell receptor library |
WO2016193300A1 (en) | 2015-06-01 | 2016-12-08 | Medigene Immunotherapies Gmbh | Method for generating antibodies against t cell receptor |
JP2018517712A (ja) | 2015-06-01 | 2018-07-05 | メディジーン イミュノテラピーズ ゲーエムベーハー | T細胞受容体特異的抗体 |
EP3310376A4 (en) | 2015-06-17 | 2019-01-23 | The California Institute for Biomedical Research | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF |
JP6630426B2 (ja) | 2015-07-06 | 2020-01-15 | ユーシービー バイオファルマ エスピーアールエル | Tau結合抗体 |
EP3344278A4 (en) | 2015-09-04 | 2019-01-23 | The California Institute for Biomedical Research | INSULIN-IMMUNOGLOBULIN FUSION PROTEINS |
EP3387019B1 (en) | 2015-12-09 | 2021-10-20 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
KR20200100858A (ko) | 2015-12-23 | 2020-08-26 | 메디진 이뮤노테라피스 게엠바하 | 수지상 세포 조성물 |
EP3529268A1 (en) | 2016-10-19 | 2019-08-28 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
US20210047425A1 (en) | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
JP2022554187A (ja) | 2019-10-24 | 2022-12-28 | ミノトール セラピューティクス インコーポレイテッド | キメラサイトカイン改変抗体およびその使用方法 |
CA3217865A1 (en) | 2021-04-28 | 2022-11-03 | Minotaur Therapeutics, Inc. | Humanized chimeric bovine antibodies and methods of use |
TW202332471A (zh) | 2021-12-01 | 2023-08-16 | 比利時商Ucb生物製藥公司 | 調配物 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5480406A (en) * | 1977-12-09 | 1979-06-27 | Tanabe Seiyaku Co Ltd | Preparation of urokinase for injection |
DE3045153A1 (de) * | 1980-11-29 | 1982-07-08 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x |
US4495278A (en) | 1981-04-27 | 1985-01-22 | Baxter Travenol Laboratories, Inc. | Process for making novel blood clotting enzyme compositions |
US4470968A (en) * | 1983-01-13 | 1984-09-11 | Miles Laboratories, Inc. | Pasteurized therapeutically active blood coagulation factor concentrates |
AT376881B (de) * | 1983-05-02 | 1985-01-10 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern |
US4540573A (en) * | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
US4952675A (en) * | 1985-02-01 | 1990-08-28 | New York University | Method for purifying antihemophilic factor |
ATE74164T1 (de) | 1985-04-22 | 1992-04-15 | Genetics Inst | Herstellung mit hoher leistung des aktivfaktors ix. |
DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
JP2708749B2 (ja) * | 1987-08-10 | 1998-02-04 | エーザイ株式会社 | 修飾型tPA含有注射用組成物 |
DE3877529T2 (de) | 1987-10-23 | 1996-11-07 | Centre Regional De Transfusion | Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung. |
US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
DE4001451A1 (de) * | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
DE4111393A1 (de) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
CA2078721A1 (en) * | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
JPH05331071A (ja) * | 1992-01-17 | 1993-12-14 | Asahi Chem Ind Co Ltd | カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法 |
US5288853A (en) * | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
DK0627924T3 (da) * | 1992-10-02 | 2001-04-30 | Genetics Inst | Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator |
ES2079994B1 (es) * | 1992-10-07 | 1996-08-01 | Cusi Lab | Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica. |
US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
-
1994
- 1994-04-26 US US08/233,663 patent/US6372716B1/en not_active Expired - Lifetime
-
1995
- 1995-04-06 ES ES95915040T patent/ES2202356T3/es not_active Expired - Lifetime
- 1995-04-06 PT PT95915040T patent/PT758248E/pt unknown
- 1995-04-06 WO PCT/US1995/004263 patent/WO1995028954A1/en active IP Right Grant
- 1995-04-06 AU AU22075/95A patent/AU695084B2/en not_active Expired
- 1995-04-06 DK DK95915040T patent/DK0758248T3/da active
- 1995-04-06 JP JP7527660A patent/JPH09512267A/ja not_active Withdrawn
- 1995-04-06 AT AT95915040T patent/ATE244015T1/de active
- 1995-04-06 DE DE69531204T patent/DE69531204T2/de not_active Expired - Lifetime
- 1995-04-06 EP EP95915040A patent/EP0758248B1/en not_active Expired - Lifetime
- 1995-04-06 CA CA002182200A patent/CA2182200C/en not_active Expired - Lifetime
-
2006
- 2006-05-22 JP JP2006141780A patent/JP4789698B2/ja not_active Expired - Lifetime
-
2007
- 2007-06-13 JP JP2007156252A patent/JP2007224052A/ja not_active Withdrawn
-
2009
- 2009-11-25 JP JP2009267797A patent/JP2010077148A/ja not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10370456B2 (en) | 2004-09-09 | 2019-08-06 | Genentech, Inc. | Process for concentration of antibodies and therapeutic products thereof |
US11767370B2 (en) | 2004-09-09 | 2023-09-26 | Genentech, Inc. | Process for concentration of antibodies and therapeutic products thereof |
JP2010530846A (ja) * | 2007-06-01 | 2010-09-16 | アコロジックス インコーポレイティッド | 高温で安定なペプチド製剤 |
Also Published As
Publication number | Publication date |
---|---|
JP4789698B2 (ja) | 2011-10-12 |
AU695084B2 (en) | 1998-08-06 |
DE69531204T2 (de) | 2004-04-22 |
PT758248E (pt) | 2003-11-28 |
US6372716B1 (en) | 2002-04-16 |
CA2182200A1 (en) | 1995-11-02 |
JP2007224052A (ja) | 2007-09-06 |
ES2202356T3 (es) | 2004-04-01 |
DK0758248T3 (da) | 2003-10-27 |
DE69531204D1 (de) | 2003-08-07 |
AU2207595A (en) | 1995-11-16 |
EP0758248A1 (en) | 1997-02-19 |
EP0758248B1 (en) | 2003-07-02 |
JP2006219500A (ja) | 2006-08-24 |
WO1995028954A1 (en) | 1995-11-02 |
JP2010077148A (ja) | 2010-04-08 |
CA2182200C (en) | 1999-02-02 |
ATE244015T1 (de) | 2003-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4789698B2 (ja) | 因子ix用処方 | |
EP0876155B1 (en) | Highly concentrated, lyophilized and liquid factor ix formulations | |
US20010031721A1 (en) | Highly concentrated, lyophilized, and liquid factor IX formulations | |
KR100450856B1 (ko) | 활성 단백질 c 제제 | |
JP3905921B2 (ja) | 凝固第▲viii▼因子を含む組成物及びその製造方法並びに安定剤としての界面活性剤の使用方法 | |
CA2490342C (en) | Stabilised solid compositions of factor vii polypeptides | |
EP1308170B1 (en) | Dried blood factor composition comprising trehalose | |
US4478829A (en) | Pharmaceutical preparation containing purified fibronectin | |
JP2018505209A (ja) | プラミノーゲンを含む医薬組成物及びその使用 | |
US6586574B1 (en) | Stabilization of freeze-dried cake | |
CN1325116C (zh) | 冷冻干燥的不含白蛋白的重组人第ⅷ凝血因子 | |
CZ243196A3 (en) | Pharmaceutical preparation containing plasminogen activators | |
EP1210361B1 (en) | Stabilisation of freeze-dried cake | |
KR101710471B1 (ko) | 건조한 트랜스글루타미나제 조성물 | |
JPH0296536A (ja) | プラスミノゲン乾燥製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060217 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060403 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060522 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070313 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20070613 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20070625 |